In our previous research, we documented the associations of plasma concentrations of interleukin 6 (IL-6) [39] and tumour necrosis factor α (TNF-α), together with its soluble receptors [38], with components of metabolic syndrome in patients with CAD. This evidence concerns the gene IL6 and metabolic syndrome.